by –News Direct–
AdAlta Ltd (ASX:1AD) CEO Dr Tim Oldham speaks with Proactive after announcing all healthy volunteers in its AD-214 Phase I extension study have successfully received three doses. The milestone allows pharmacokinetic and receptor engagement analysis to be completed on schedule. The results confirm the favourable tolerability profile observed at lower doses. Dr Oldham says the company has also materially progressed several partnering and project financing discussions over the past month to help progress phase II studies.
Oldham said: We continue to be grateful to the volunteers participating in this Phase 1 extension study.
The favourable safety profile of AD-214 continues to be demonstrated at the anticipated Phase 2 clinical study doses.
This study also supports our partnering program for AD-214 and we are pleased to have materially progressed several partnering and project financing discussions over the past month to help progress AD-214 into Phase 2 studies.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/adalta-making-material-progress-on-partnering-talks-942381937
AdAlta Ltd
COMTEX_442330815/2655/2023-10-23T11:44:09
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.